Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2018 Jun 7;8(6):54. doi: 10.1038/s41408-018-0096-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — The graph shows the results of a competing risk regression analysis. Death was counted as a competitive event. VTE before the start of systemic therapy were considered heralding events and were counted as events at time 0, while VTE during the first nine months from treatment start was considered treatment-related events. Subdistribution hazard risk was 5.2-fold (95% CI, 3.1–8.8) for patients with the risk factors reduced performance status (ECOG > 2) and/or bulky disease (>10 cm), and 8.0-fold (95% C.I., 3.7–17.5) for patients with PCNSL.Analysis of the treatment-related VTE in 803 patients, after exclusion of the 54 ones who presented with VTE before the start of therapy, confirmed a VTE risk gradient similar to that of the overall cohort (see text) (5/29, 17.2% in PCNSL, 25/333, 7.5% in the bulk and/or ECOG group, and 11/441, 2.5% in the low-risk group)